Dr. Michael Roizen Longevity Protocol: What Clinicians Should Tell Patients

Who Is Dr. Michael Roizen?

Dr. Michael Roizen is an internist and anesthesiologist who served as Cleveland Clinic's first Chief Wellness Officer from 2007 until his transition to emeritus status. He developed the RealAge concept, a biological-age calculator that estimates physiological age based on lifestyle inputs. His books, co-authored with Dr. Mehmet Oz, have sold more than 30 million copies worldwide.

From Academic Medicine to Public Health Advocacy

Roizen's career trajectory matters for clinicians evaluating his claims. He chaired the Department of Anesthesia at the University of Chicago before joining Cleveland Clinic. That institutional affiliation lends weight but does not exempt his public recommendations from scrutiny. His peer-reviewed publication record spans anesthesia pharmacology and perioperative risk, not longevity trials 1.

The RealAge Framework

The RealAge calculator assigns biological age based on 125 health-related inputs. A 2005 analysis published in the BMJ noted that while composite risk scores can motivate behavior change, their predictive validity depends heavily on the quality of the input variables 2. Clinicians should treat RealAge as a patient engagement tool, not a validated clinical biomarker on par with coronary calcium scoring or epigenetic clocks.

What Does Dr. Michael Roizen Take Daily?

Roizen has outlined his personal supplement and lifestyle regimen across multiple interviews and in his books. He has stated publicly that he takes vitamin D3 (2,000 IU), DHA omega-3 (900 mg), and a baby aspirin (81 mg, though he has noted re-evaluating this after updated USPSTF guidance). He also reports eating meals within an approximately 12-hour window and walking 10,000 steps per day.

Vitamin D3: 2,000 IU

The Endocrine Society's 2024 clinical practice guideline recommends 1,500 to 2,000 IU daily for adults at risk of deficiency, aligning with Roizen's reported dose 3. The VITAL trial (N=25,871) found that 2,000 IU of vitamin D3 did not significantly reduce the incidence of invasive cancer or cardiovascular events over 5.3 years in the overall population, though subgroup analyses suggested a 17% cancer mortality reduction after excluding the first two years of follow-up 4. Tell patients: the dose is safe and guideline-concordant for those with risk factors, but it is not a proven life-extension agent for vitamin D-replete individuals.

Omega-3 DHA: 900 mg

Roizen specifically emphasizes DHA over EPA. The REDUCE-IT trial (N=8,179) demonstrated that icosapent ethyl (pure EPA, 4 g/day) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides 5. For DHA, the evidence is less definitive. A 2020 Cochrane review of 86 RCTs concluded that increasing omega-3 intake slightly reduces coronary heart disease mortality and events but has little or no effect on all-cause mortality 6. Clinicians should clarify that Roizen's DHA-specific preference reflects his interpretation of cognitive-health data, not a cardiovascular consensus.

Baby Aspirin: Evolving Guidance

Roizen long advocated daily low-dose aspirin. The USPSTF in 2022 downgraded its recommendation for primary prevention of cardiovascular disease in adults aged 40 to 59, assigning a "C" grade (individual decision) and recommending against initiation in adults 60 and older 7. The ASPREE trial (N=19,114) found no benefit for disability-free survival among healthy adults over 70 and showed a higher rate of major hemorrhage 8. Roizen has publicly acknowledged re-evaluating this component. This is a useful teaching moment: even well-known physicians update their protocols when evidence shifts.

The Exercise Pillar: 10,000 Steps and Strength Training

Roizen promotes a daily target of 10,000 steps plus regular resistance exercise. This section carries the strongest evidence of any pillar in his protocol.

Steps and All-Cause Mortality

A 2022 meta-analysis in The Lancet (15 studies, N=47,471) found that every additional 1,000 steps per day was associated with a 15% reduction in all-cause mortality in adults aged 60 and older, with benefits plateauing near 6,000 to 8,000 steps 9. The 10,000-step target, originally derived from a 1960s Japanese pedometer marketing campaign, slightly overshoots the observed plateau. But the clinical harm of exceeding the threshold is nil. Telling a patient "aim for 10,000" is a simple, memorable heuristic that keeps them well above the dose-response curve's steepest portion.

Resistance Training and Aging

The 2018 Physical Activity Guidelines Advisory Committee Scientific Report confirmed that muscle-strengthening activities on two or more days per week are associated with reduced risk of all-cause mortality, cardiovascular disease, type 2 diabetes, and cancer 10. Roizen's inclusion of strength training is well-supported. Clinicians should emphasize progressive overload and proper form, particularly for patients over 65 where sarcopenia accelerates functional decline.

Stress Management and Sleep: The Underrated Pillars

Roizen frequently discusses stress reduction through meditation and adequate sleep as age-slowing interventions. These recommendations are directionally correct but difficult to prescribe with the same precision as a supplement dose.

Chronic Stress and Telomere Biology

Dr. Elissa Epel's research at UCSF demonstrated that perceived psychological stress is associated with shorter telomere length and lower telomerase activity in peripheral blood mononuclear cells. In her landmark 2004 study (N=58 premenopausal women), those in the highest-stress group had telomere shortening equivalent to approximately 10 additional years of aging 11. Roizen cites this data frequently. The clinical translation: chronic caregiver stress, unmanaged anxiety, and sleep deprivation have measurable biological costs that lifestyle counseling can partially address.

Sleep Duration and Cardiometabolic Risk

The American Heart Association added sleep as the eighth component of its Life's Essential 8 cardiovascular health metric in 2022 12. Adults sleeping fewer than 7 hours per night show higher rates of obesity, hypertension, type 2 diabetes, and coronary heart disease. Roizen's public recommendation of 7 to 8 hours nightly is consistent with AHA and CDC guidance 13. For clinicians, the actionable step is screening for sleep disorders (particularly obstructive sleep apnea) before assuming poor sleep is purely behavioral.

Caloric Restriction and Time-Restricted Eating

Roizen has discussed intermittent fasting and caloric awareness in his books and public appearances. He reportedly eats within a roughly 12-hour daily window, a pattern less restrictive than the 16:8 protocols that dominate popular media.

What CALERIE Showed

The CALERIE trial (N=218) is the only completed RCT of sustained caloric restriction in non-obese humans. Participants assigned to 25% caloric restriction achieved approximately 12% reduction over two years and showed improvements in cardiometabolic biomarkers including fasting insulin, LDL cholesterol, and C-reactive protein 14. The 2-year follow-up demonstrated that these benefits persisted. Roizen does not advocate aggressive caloric restriction. His 12-hour eating window is closer to a circadian-alignment strategy than a true fasting protocol.

Clinical Translation

A 12-hour eating window is one of the least controversial dietary interventions a clinician can recommend. It requires no calorie counting, aligns with circadian physiology, and is achievable for most patients. The New England Journal of Medicine's 2019 review of intermittent fasting noted that time-restricted eating improves insulin sensitivity and reduces oxidative stress markers in human studies, though long-term mortality data remain limited 15.

How Clinicians Should Frame Roizen's Protocol for Patients

Patients who follow Dr. Roizen's public advice will inevitably bring it up during clinical encounters. The challenge is not dismissing their interest while redirecting toward evidence-based medicine.

Start With What He Gets Right

Roizen's emphasis on exercise, sleep, stress management, and moderate supplementation maps closely to existing clinical guidelines. The AHA, ACSM, and Endocrine Society all support versions of these recommendations. Acknowledge the overlap. Patients feel validated when their physician does not reflexively discount a public figure they trust.

Flag the Gaps

Roizen's public protocol does not address cancer screening adherence, vaccination, blood pressure pharmacotherapy, statin eligibility, or diabetes prevention with metformin. These omissions are expected in a wellness-focused message aimed at a general audience, but clinicians must fill them. A patient who walks 10,000 steps daily and takes vitamin D but skips colonoscopy is not optimizing longevity.

As Dr. Donald Lloyd-Jones, chair of the AHA committee that developed Life's Essential 8, stated: "Cardiovascular health is more than the absence of disease. It is defined by both health behaviors and health factors together" 12.

Avoid the Celebrity-Endorsement Trap

The halo effect of a Cleveland Clinic affiliation can lead patients to over-weight Roizen's recommendations relative to the underlying evidence. Clinicians should note that institutional affiliation does not equal institutional endorsement of a personal supplement regimen. Cleveland Clinic's own published position on vitamin D supplementation for the general population, for instance, aligns with the more conservative Institute of Medicine recommendation of 600 to 800 IU daily for most adults, not the 2,000 IU Roizen takes 16.

Longevity Medicine: Where the Field Is Heading

Roizen's "Great Age Reboot" (2022) anticipates advances in gene therapy, senolytic drugs, and organ regeneration. These predictions sit well outside current clinical practice, but the trajectory is worth tracking.

Senolytics

The dasatinib-plus-quercetin combination has shown senolytic activity in human adipose tissue explants and early-phase clinical studies in idiopathic pulmonary fibrosis 17. No large RCT has reported all-cause mortality outcomes. Patients who ask about senolytics based on Roizen's writing should be told the science is promising but premature for clinical use outside of trials.

GLP-1 Receptor Agonists and Aging

Roizen has publicly expressed interest in GLP-1 receptor agonists beyond their metabolic indications. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes 18. Whether this cardiovascular benefit translates into a longevity signal independent of weight loss remains an open question, but it has reshaped the clinical conversation about pharmacological aging interventions.

Rapamycin and mTOR Inhibition

The mechanistic target of rapamycin (mTOR) pathway has been a focal point of preclinical longevity research. Rapamycin extended median lifespan by 9% to 14% in the National Institute on Aging's Interventions Testing Program in mice 19. Human data are limited to small studies of immune function in elderly volunteers, where low-dose mTOR inhibition improved influenza vaccine response by approximately 20% 20. This is an area Roizen discusses in the context of future medicine, not current self-experimentation.

The Bottom Line for Your Next Patient Encounter

When a patient says "I'm following Dr. Roizen's protocol," the correct clinical response is neither dismissal nor uncritical acceptance. Validate the exercise and sleep components. Confirm vitamin D status with a 25-hydroxyvitamin D level before endorsing 2,000 IU. Review aspirin use against current USPSTF guidance. Screen for the preventive care gaps his public messaging does not cover. And frame every conversation in the language of shared decision-making, where the patient's motivation meets the clinician's evidence base.

Serum 25-hydroxyvitamin D target: 30 to 50 ng/mL per the Endocrine Society's 2024 guideline 3.